Novo Nordisk has signed an agreement with Hims & Hers Health that will allow the telehealth provider to offer FDA‑approved versions of Ozempic and Wegovy at self‑pay prices comparable to other digital ...

On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (HIMS +5.89%), an estimated $18.07 million trade based on quarterly ...

Hims & Hers Health Inc HIMS shares are rising higher on Tuesday. Multiple analysts upgraded the stock following the company’s deal with Novo Nordisk this week. Hims & Hers has struck a new agreement ...

After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 maker ...

Check out some of the companies making the biggest moves midday: Hims & Hers Health — Shares of the telehealth company jumped 3%. Bank of America upgraded the stock to neutral from underperform after ...

Amid the company’s efforts to resolve issues raised during an FDA inspection early last year, Novo Nordisk’s operating base in Plainsboro, New Jersey—already the recipient of a recent Form 483—has ...

HIMS stock has staged a sharp rebound after drugmaker Novo Nordisk dropped its lawsuit against the company. Is the stock now a buy?

The telehealth platform’s shares jumped more than 40% after the news that it will sell Ozempic and Wegovy—and no longer faces a lawsuit from the Danish pharma giant.

Whether President Trump signaled that he may soon end the military strikes is weighing on the minds of investors, executives and others.

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss ...

Ozempic maker Novo Nordisk gets another downgrade. The end's in sight for its duopoly status, says TD Cowen. TD Cowen downgraded Novo Nordisk to hold. Novo Nordisk on Tuesday received a broker ...